PMC:7556165 / 71123-72259
Annnotations
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T195 | 120-127 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T196 | 334-341 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T397 | 12-17 | Species | denotes | human | NCBItxid:9606 |
T398 | 272-280 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T399 | 652-662 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T400 | 652-656 | Species | denotes | SARS | NCBItxid:694009 |
T401 | 688-693 | Species | denotes | human | NCBItxid:9606 |
T402 | 721-726 | Species | denotes | human | NCBItxid:9606 |
T403 | 882-892 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T404 | 882-886 | Species | denotes | SARS | NCBItxid:694009 |
T405 | 989-999 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T406 | 989-993 | Species | denotes | SARS | NCBItxid:694009 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T421 | 0-204 | Sentence | denotes | Recombinant human ACE 2, rhACE2 (hrsACE2, APN01, GSK2586881), sequesters circulating viral particles interfering with S-protein binding to its host target, beside its role in regulating the systemic RAAS. |
T422 | 205-560 | Sentence | denotes | Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017). |
T423 | 561-767 | Sentence | denotes | Moreover, it has been demonstrated that rhACE2 can significantly block the early stages of SARS-CoV-2 infections in engineered human blood vessel organoids and human kidney organoids (Monteil et al., 2020). |
T424 | 768-929 | Sentence | denotes | In this context, Procko (2020) was able to engineer hACE2 sequences to obtain soluble receptors able to sequester SARS-CoV-2 RBD and inhibit its cell attachment. |
T425 | 930-1136 | Sentence | denotes | Remarkably, combinatorial mutants enhanced ACE2 binding to SARS-CoV-2 RBD by an order of magnitude, as compared to the wild type receptor form, and targeted ACE2 mutations might provide further improvement. |
LitCovid-sample-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T151 | 694-706 | Body_part | denotes | blood vessel | http://purl.obolibrary.org/obo/UBERON_0001981 |
T152 | 727-733 | Body_part | denotes | kidney | http://purl.obolibrary.org/obo/UBERON_0002113 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
1960 | 118-127 | Gene | denotes | S-protein | Gene:43740568 |
1961 | 820-825 | Gene | denotes | hACE2 | Gene:59272 |
1962 | 973-977 | Gene | denotes | ACE2 | Gene:59272 |
1963 | 1087-1091 | Gene | denotes | ACE2 | Gene:59272 |
1965 | 281-289 | Species | denotes | patients | Tax:9606 |
1966 | 521-529 | Species | denotes | patients | Tax:9606 |
1967 | 688-693 | Species | denotes | human | Tax:9606 |
1968 | 721-726 | Species | denotes | human | Tax:9606 |
1969 | 882-892 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1970 | 989-999 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1971 | 415-421 | Chemical | denotes | rhACE2 | |
1972 | 601-607 | Chemical | denotes | rhACE2 | |
1973 | 272-280 | Disease | denotes | COVID-19 | MESH:C000657245 |
1974 | 535-539 | Disease | denotes | ARDS | MESH:D012128 |
1975 | 652-673 | Disease | denotes | SARS-CoV-2 infections | MESH:C000657245 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T6198 | 18-21 | Protein | denotes | ACE | https://www.uniprot.org/uniprot/Q9GLN7|https://www.uniprot.org/uniprot/Q9GLN6|https://www.uniprot.org/uniprot/Q9EQM9|https://www.uniprot.org/uniprot/Q8CFN1|https://www.uniprot.org/uniprot/Q7TMC6|https://www.uniprot.org/uniprot/Q7M4L4|https://www.uniprot.org/uniprot/Q6GTS2|https://www.uniprot.org/uniprot/Q59GY8|https://www.uniprot.org/uniprot/Q53YX9|https://www.uniprot.org/uniprot/Q50JE5|https://www.uniprot.org/uniprot/Q10751|https://www.uniprot.org/uniprot/Q0GA41|https://www.uniprot.org/uniprot/P47820|https://www.uniprot.org/uniprot/P22968|https://www.uniprot.org/uniprot/P22967|https://www.uniprot.org/uniprot/P22966|https://www.uniprot.org/uniprot/P12822|https://www.uniprot.org/uniprot/P12821|https://www.uniprot.org/uniprot/P12820|https://www.uniprot.org/uniprot/P09470|https://www.uniprot.org/uniprot/O02852|https://www.uniprot.org/uniprot/E7EU16|https://www.uniprot.org/uniprot/B4DXI3|https://www.uniprot.org/uniprot/B0LPF0|https://www.uniprot.org/uniprot/Q9VJV3 |
T6223 | 118-127 | Protein | denotes | S-protein | https://www.uniprot.org/uniprot/Q9D080|https://www.uniprot.org/uniprot/Q9BSH7|https://www.uniprot.org/uniprot/Q91X32|https://www.uniprot.org/uniprot/Q8VII4|https://www.uniprot.org/uniprot/Q5SYG4|https://www.uniprot.org/uniprot/P48819|https://www.uniprot.org/uniprot/P29788|https://www.uniprot.org/uniprot/P22458|https://www.uniprot.org/uniprot/P04004|https://www.uniprot.org/uniprot/P01141|https://www.uniprot.org/uniprot/B2R7G0 |
T6234 | 893-896 | Protein | denotes | RBD | https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022 |
T6243 | 973-977 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
T6244 | 1000-1003 | Protein | denotes | RBD | https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022 |
T6253 | 1087-1091 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T290 | 143-147 | http://purl.obolibrary.org/obo/IDO_0000531 | denotes | host |
T291 | 663-676 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections in |
T292 | 694-699 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T293 | 913-917 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T458 | 120-127 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T459 | 334-341 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T460 | 694-706 | Body_part | denotes | blood vessel | http://purl.org/sig/ont/fma/fma63183 |
T461 | 727-733 | Body_part | denotes | kidney | http://purl.org/sig/ont/fma/fma7203 |
T462 | 913-917 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T420 | 272-280 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T421 | 535-539 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
T422 | 652-662 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T423 | 652-656 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T424 | 663-676 | Disease | denotes | infections in | http://purl.obolibrary.org/obo/MONDO_0005550 |
T425 | 882-892 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T426 | 882-886 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T427 | 989-999 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T428 | 989-993 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sample-PD-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T137 | 694-706 | http://purl.obolibrary.org/obo/MAT_0000393 | denotes | blood vessel |
T138 | 694-699 | http://purl.obolibrary.org/obo/MAT_0000083 | denotes | blood |
T139 | 694-699 | http://purl.obolibrary.org/obo/MAT_0000315 | denotes | blood |
T140 | 727-733 | http://purl.obolibrary.org/obo/MAT_0000119 | denotes | kidney |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1959 | 18-23 | Gene | denotes | ACE 2 | Gene:59272 |
1960 | 118-127 | Gene | denotes | S-protein | Gene:43740568 |
1961 | 820-825 | Gene | denotes | hACE2 | Gene:59272 |
1962 | 973-977 | Gene | denotes | ACE2 | Gene:59272 |
1963 | 1087-1091 | Gene | denotes | ACE2 | Gene:59272 |
1964 | 12-17 | Species | denotes | human | Tax:9606 |
1965 | 281-289 | Species | denotes | patients | Tax:9606 |
1966 | 521-529 | Species | denotes | patients | Tax:9606 |
1967 | 688-693 | Species | denotes | human | Tax:9606 |
1968 | 721-726 | Species | denotes | human | Tax:9606 |
1969 | 882-892 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1970 | 989-999 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1971 | 415-421 | Chemical | denotes | rhACE2 | |
1972 | 601-607 | Chemical | denotes | rhACE2 | |
1973 | 272-280 | Disease | denotes | COVID-19 | MESH:C000657245 |
1974 | 535-539 | Disease | denotes | ARDS | MESH:D012128 |
1975 | 652-673 | Disease | denotes | SARS-CoV-2 infections | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T421 | 0-204 | Sentence | denotes | Recombinant human ACE 2, rhACE2 (hrsACE2, APN01, GSK2586881), sequesters circulating viral particles interfering with S-protein binding to its host target, beside its role in regulating the systemic RAAS. |
T422 | 205-560 | Sentence | denotes | Taken together, these activities may offer therapeutic benefits in COVID-19 patients, although the large molecular weight of the protein may potentially limit its effects on local RAAS (Gheblawi et al., 2020). rhACE2 has already undergone phase 1 and 2 clinical trials in healthy volunteers and in a small cohort of patients with ARDS (Khan et al., 2017). |
T423 | 561-767 | Sentence | denotes | Moreover, it has been demonstrated that rhACE2 can significantly block the early stages of SARS-CoV-2 infections in engineered human blood vessel organoids and human kidney organoids (Monteil et al., 2020). |
T424 | 768-929 | Sentence | denotes | In this context, Procko (2020) was able to engineer hACE2 sequences to obtain soluble receptors able to sequester SARS-CoV-2 RBD and inhibit its cell attachment. |
T425 | 930-1136 | Sentence | denotes | Remarkably, combinatorial mutants enhanced ACE2 binding to SARS-CoV-2 RBD by an order of magnitude, as compared to the wild type receptor form, and targeted ACE2 mutations might provide further improvement. |